Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1

Liwei Dong1
Hongge Wang1
Jiajing Niu1
Mingwei Zou2
Nuoting Wu1
Debin Yu1
Ye Wang1
Zhihua Zou1

1Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin Province, People’s Republic of China; 2Department of Psychology, College of Liberal Arts and Social Sciences, University of Houston, Houston, TX, USA

Abstract: Inhibition of the nucleotide pool sanitizing enzyme MTH1 causes extensive oxidative DNA damages and apoptosis in cancer cells and hence may be used as an anticancer strategy. As natural products have been a rich source of medicinal chemicals, in the present study, we used the MTH1-catalyzed enzymatic reaction as a high-throughput in vitro screening assay to search for natural compounds capable of inhibiting MTH1. Echinacoside, a compound derived from the medicinal plants Cistanche and Echinacea, effectively inhibited the catalytic activity of MTH1 in an in vitro assay. Treatment of various human cancer cell lines with Echinacoside resulted in a significant increase in the cellular level of oxidized guanine (8-oxoguanine), while cellular reactive oxygen species level remained unchanged, indicating that Echinacoside also inhibited the activity of cellular MTH1. Consequently, Echinacoside treatment induced an immediate and dramatic increase in DNA damage markers and upregulation of the G1/S-CDK inhibitor p21, which were followed by marked apoptotic cell death and cell cycle arrest in cancer but not in noncancer cells. Taken together, these studies identified a natural compound as an MTH1 inhibitor and suggest that natural products can be an important source of anticancer agents.

Keywords: Echinacoside, MTH1, 8-oxoG, DNA damage, apoptosis, cell cycle arrest

Introduction

The cellular and mitochondrial nucleoside triphosphate (NTP) and deoxynucleoside triphosphate (dNTP) pool is a significant target of various reactive oxygen species (ROS).1–3 Because the specificity of DNA polymerases is less than perfect,4,5 oxidized dNTPs can be incorporated into newly synthesized DNA to cause genetic aberrations if not fixed.6 For example, the major oxidized base in the nucleotide pool, 8-oxoguanine (8-oxoG), can base pair with cytosine and adenine. When inserted into opposite adenine during DNA replication, it can potentially cause T:A = G:C transversion,7 which is one of the most common mutations found in human cancers.8,9 Although most of the oxidized free dNTPs are removed by nucleotide pool sanitizing enzymes, studies in the past have revealed that the nucleotide pool is still an important source of oxidized bases in DNA molecules and a significant contributor of oxidative DNA damages.3,10

Mammalian cells are armed with sophisticated defense mechanisms to minimize ROS-induced genomic lesions. Nucleotide pool sanitizing enzymes hydrolyze oxidized dNTPs and NTPs, thus preventing their incorporation into DNA and RNA molecules.11,12 MTH1, a member of the Nudix hydrolase superfamily (hence also called NUDT1),13 is a triphosphatase responsible for removing oxidized purine NTPs and dNTPs (8-oxodGTP, 2-OH-dATP, 8-OH-GTP, and 2-OH-ATP) from the nucleotide pools.14 Since 8-oxoguanine (8-oxoG) is the major oxidized base inside cells, MTH1 is
the most important enzyme for the sanitization of nucleotide pools. Nevertheless, even under the surveillance by the nucleotide pool sanitizing enzymes, a significant portion of oxidized dNTPs is incorporated into DNA, and bases in DNA molecules can also be oxidized directly by ROS. Cells then rely on more elaborated strategies involving various DNA glycosylases, such as OGG1 and MUTYH, and DNA repair processes, including base excision repair (BER) and mismatch repair (MMR), to fix problematic bases in DNA molecules. BER and MMR normally repair numerous oxidized bases in DNA per day and thus play important roles in protecting the integrity and stability of the genome.

In cells that are under elevated oxidative stress, increased incorporation of oxidized nucleotides into DNA may overwhelm the cellular repair capacity and trigger DNA damage response (DDR). Persistent DDR signaling will lead to cell cycle arrest, premature cellular senescence, or apoptosis, thus setting a barrier for tumorigenesis. Yet, although cancer cells display highly increased oxidative tension and generate a potentially lethal burden of oxidized nucleotides, they can survive the DDR-associated senescence or apoptosis. A large number of studies have shown that MTH1, by effectively removing the dangerously abundant 8-oxodGTP and 2-OH-dATP in tumors than in the surrounding normal tissues, plays a key role in the development of cancer. MTH1 was found to be overexpressed in different types of cancer, and 8-oxoG level and the extent of oxidative DNA lesions were lower in tumors than in the surrounding normal tissues. Functionally, the overexpression of MTH1 significantly reduced the number of DNA mutations seen in MMR-deficient mouse embryonic fibroblasts and allowed cells to overcome oncogenic Ras-induced premature cellular senescence and apoptosis; whereas the suppression of MTH1 prevented the development of cancer in OGG1-deficient mice and promoted ROS-induced DDR and cellular senescence in Ras-transformed cells. Thus, although MTH1 plays a protective role by preventing ROS-induced mutations in healthy cells, these studies found that MTH1 is particularly required for the emergence and survival of cancer cells. Recent studies have provided more evidence to support the role of MTH1 in cancer development. Suppression of MTH1 by RNAi or small molecule inhibitors in various cancer cell lines resulted in markedly increased incorporation of 8-oxodG into genomic DNA, leading to extensive DNA damages, apoptotic cell death, and reduced cancer cell survival. In mouse xenograft studies, inhibition of MTH1 efficiently suppressed the growth of cancer explants. Importantly, suppressing MTH1 did not impact the growth and survival of normal cells, probably because normal cells have lower ROS and hence are less dependent on MTH1 for survival. These findings suggest that inhibition of MTH1 is a promising novel strategy to fight cancer.

Natural products have been a rich source of medicinal compounds. Many modern therapeutics, including anticancer drugs, have been derived from herbal or botanical preparations. Still, a large number of traditional herbs proposed to possess various therapeutic properties remain to be characterized, largely due to difficulties in controlling their compositions to unambiguously define their efficacy and mechanisms of action. New approaches that allow for detection of active compounds and analysis of molecular mechanisms are needed. In this regard, target-guided high-throughput in vitro screening can be instrumental in finding mechanistically defined medicinal compounds from natural resources. In the present study, we used the MTH1-catalyzed enzymatic reaction as a high-throughput in vitro assay to search for natural compounds that can inhibit MTH1. Surprisingly, the screening revealed that Echinacoside, a natural product that is best known for its potent antioxidative activity, is capable of inhibiting MTH1.

Materials and methods
Materials
Natural herbal compounds were purchased from Yuanye Biological Technology Co., Shanghai, People’s Republic of China. The name, catalog number, Chemical Abstracts Service (CAS) registry number, and purity of each compound are listed in Table S1. Stock solutions of the compounds were prepared in 100% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO, USA), and working solutions were prepared in assay buffer or complete cell culture medium. The same solution without the test compound but containing the same amount of DMSO was used as vehicle control. (S)-crizotinib was purchased from Selleck Chemicals, Houston, TX, USA.

In vitro screening
The in vitro enzymatic assay used to screen natural herbal compounds followed the procedures described by Gad et al. Briefly, serial dilutions of individual compounds were prepared in the assay buffer consisting of 100 mM Tris-acetate (pH 8.0), 40 mM NaCl, 10 mM Mg acetate, 0.005% Tween 20, and 1 mM DTT. Next, 0.5 nM recombinant human MTH1 (Abcam, Cambridge, UK), 100 μM dGTP (Thermo Fisher Scientific, Waltham, MA, USA), and 0.2 U/mL inorganic pyrophosphatase (Thermo Fisher Scientific) were added, and the plates were incubated on a plate shaker for 1 hour at

Dong et al

OncoTargets and Therapy 2015:8

www.dovepress.com

Dovepress

submit your manuscript | www.dovepress.com

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 13-Dec-2018
For personal use only.
room temperature. The final reaction volume was 100 µL in a 96-well plate. At the end of the reaction, malachite green (J&K Scientific, Beijing, People’s Republic of China) was added, and the plates were incubated at room temperature for another 15 minutes. Absorbance at 630 nm was measured by a BioRad 680 microplate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA). Inhibitory concentration (IC₅₀) values were determined by nonlinear regression analysis using the GraphPad Prism software.

**Cell culture**

Human MG-63 osteosarcoma, SK-HEP-1 hepatocarcinoma, MCF7 breast cancer, SW480 colorectal cancer, HEK293 embryonic kidney, and mouse NIH/3T3 fibroblast cell lines were from American Type Culture Collection, and the human normal liver cell line L-O2 was purchased from KenGen Biotech, Nanjing, People’s Republic of China. These cells were from American Type Culture Collection, and the human normal liver cell line L-O2 was purchased from KenGen Biotech, Nanjing, People’s Republic of China. These cells were maintained at 37°C in a humidified atmosphere with 5% CO₂, following instructions given by the providers. No ethics statement was required from the institutional review board for the use of these cell lines.

**Measurement of intracellular 8-oxoG**

Intracellular 8-oxoG levels were measured by staining with Cy3-conjugated avidin. A total of 1×10⁴ cells were seeded on a round coverslip in 12-well plates. Next day, the cells were treated with 0 µM, 15 µM, 30 µM, 60 µM, or 80 µM Echinacoside for 5 hours, 12 hours, or 24 hours and were then fixed with ice-cold methanol for 20 minutes, followed by incubation in Tris-buffered saline (TBS) with 0.1% Triton X-100 (Sigma-Aldrich) for 15 minutes. The samples were blocked in TBS with 0.1% Triton X-100 and 15% fetal bovine serum for 1 hour at room temperature. Fixed cells were stained for 2 hours at room temperature with a primary antibody against 8-oxoG (mouse monoclonal anti-8-oxoG, Abcam), 53BP1 (rabbit anti-53BP1; Bethyl Laboratories, Montgomery, TX, USA), or active caspase-3 (rabbit anti-caspase-3, Bioss, Beijing, People’s Republic of China), followed by staining with an Alexa 488-conjugated donkey antimouse (Abcam) or Cy3-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) secondary antibody for 1 hour at room temperature. After washing in PBS for 3 times for 5 minutes, the coverslips were sealed on glass slides in VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). Images were taken by a Zeiss LCM 510 confocal microscope.

**Colony formation assay**

The day before treatment, cells were seeded in a six-well plate at a concentration of 1×10⁴ cells per well. They were then treated with 0 µM, 60 µM, or 80 µM Echinacoside for 7 days. After washing with PBS, cells were fixed with ice-cold methanol and stained with crystal violet solution (Sigma-Aldrich) (0.5% in 25% methanol) in blocking solution for 1 hour at 37°C. After washing in phosphate-buffered saline (PBS) for 3 times for 5 minutes, the coverslips were sealed on glass slides in VECTASHIELD Mounting Medium with 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). Images were taken and analyzed by a Zeiss LCM 510 confocal microscope.

**MTT assay**

One day before treatment, cells were seeded in 96-well plates at a concentration of 1×10⁴ cells per well, followed by treatment with serial dilutions of Echinacoside for 24 hours or 48 hours, or with 60 µM Echinacoside for 5 hours, 12 hours, or 24 hours. The medium was removed, and the cells were washed with PBS, and then, 20 µL of 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT) solution (5 mg/mL in PBS, pH 7.2) (Thermo Fisher Scientific) was added to each well. The plates were incubated at 37°C for another 4 hours. At the end, the MTT solution was removed and 150 μL of DMSO was added to each well. The plates were incubated on a plate shaker for 10 minutes, and absorbance at 570 nm was measured by a BioRad 680 microplate reader. Each experiment was conducted twice in triplicate. Data were analyzed using the GraphPad Prism software. IC\textsubscript{50} values were determined using nonlinear regression analysis.

### Cell cycle analysis
Cells in six-well plates were treated with 0 μM, 60 μM, or 80 μM Echinacoside for 24 hours, harvested with trypsin (Life Technologies, Carlsbad, CA, USA), washed twice with PBS, and then fixed with ice-cold ethanol (70%) for 2 hours at −20°C. Fixed cells were washed twice in cold PBS and resuspended in 300 μL of freshly prepared PBS with 0.1% Triton X-100, 0.2 mg/mL DNase-free RNase A (Sigma-Aldrich), 10 μg/mL propidium iodide (PI) (Hoffman-La Roche Ltd., Basel, Switzerland). After incubation at 37°C in the dark for 20 minutes, the cells were filtered through a Filcon nylon mesh (BD Biosciences), loaded onto the FACSCalibur flow cytometer, and analyzed using the ModFit software (BD Biosciences).

### DNA fragmentation analysis
Cells grown in six-well plates were treated with 0 μM, 60 μM, or 80 μM Echinacoside for 24 hours and fixed in ice-cold 4% paraformaldehyde (Sigma-Aldrich) for 20 minutes. After washing with PBS, cells were sealed in VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). Nuclear morphology was photographed with an Olympus fluorescent microscope. To detect DNA fragmentation on agarose gels, DNA was extracted using the QIAamp DNA micro kit (Qiagen NV, Venlo, the Netherlands), and electrophoresis was performed on 2% agarose gels containing 0.1 μg/mL ethidium bromide.

### Analysis of apoptosis by flow cytometry
Apoptotic cells were examined using an Annexin V-FITC Apoptosis detection kit (Bestbio, Shanghai, People’s Republic of China), following the manufacturer’s instructions. Cells grown in 96-well plates were treated with 0 μM, 15 μM, 30 μM, 60 μM, 80 μM, or 160 μM Echinacoside for 2 hours, 5 hours, 12 hours, or 24 hours, washed twice with PBS, and then resuspended in a binding buffer. Next, 5 μL of Annexin V-FITC and 5 μL of PI (Roche) were added sequentially, and the cells were incubated for 15 minutes in the dark at room temperature. The cells were loaded onto the FACSCalibur flow cytometer (BD Biosciences), and data were analyzed using the Cell Quest software (BD Biosciences).

### Western blot analysis
Cells grown in six-well plates were treated with 0 μM, 60 μM, or 80 μM Echinacoside for 5 hours, 12 hours, or 24 hours, washed twice with PBS, and scraped off the plate using 100 μL of radioimmunoprecipitation buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM Tris, pH 8.0) (Sigma-Aldrich) containing 1 mM phenylmethane sulfonfluoride. Samples were centrifuged at 12,000×g for 20 minutes at 4°C. Protein concentrations in the supernatants were determined by the Bradford reagent (Dingguo, Changchun, People’s Republic of China). Samples were denatured at 95°C for 10 minutes and separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel. After electrophoresis, proteins were transferred to polyvinylidene fluoride membranes (Millipore), followed by blocking in Tris-buffered saline with Tween 20 (10 mM Tris, pH 7.5; 100 mM NaCl; 0.1% Tween 20) containing 5% (w/v) nonfat milk for 1 hour at room temperature. Blots were probed with primary antibodies against p21 (Abcam), poly (ADP-ribose) polymerase (Bioss), or activated caspase-3 (Bioss), followed by horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Signals were developed using the enhanced chemiluminescence Western blotting detection kit (Transgen Biotech, Changchun, People’s Republic of China). The experiments were repeated three times.

### Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was measured using the JC-1 dye (Biotecnology), following the manufacturer’s instructions. Cells grown in six-well plates were treated with 0 μM, 60 μM, or 80 μM Echinacoside for 5 hours, 12 hours, or 24 hours, washed twice in PBS, and then incubated with JC-1 for 20 minutes. Images were taken using an Olympus fluorescent microscope.

### Statistical analysis
Statistical analysis was performed using the GraphPad Prism Software. Significance was calculated using one-way analysis of variance, and P<0.05 was considered statistically significant. Results were expressed as mean ± standard deviation.
Results
Identification of Echinacoside as an MTH1 inhibitor
To search for natural compounds capable of inhibiting MTH1, we used the MTH1-catalyzed enzymatic reaction as a high-throughput in vitro screening assay. Besides oxidized purine nucleotides, MTH1 can also hydrolyze normal deoxyguanosine triphosphate to generate deoxyguanosine monophosphate and pyrophosphate. In the presence of excess inorganic pyrophosphatase, all pyrophosphates are converted into inorganic phosphates, which can be quantified using a malachite green-based absorbance assay, thus allowing for indirect measurement of MTH1 activity.

To test the assay system, we first measured the effect of (S)-crizotinib, a compound with proven potency as an MTH1 inhibitor. The result showed that (S)-crizotinib indeed potently inhibited MTH1 (Figure 1A) with an IC₅₀ of 500 nM, which was sevenfold higher than that reported by Huber et al (72 nM). This was likely due to the differences in the detection methods or sources of chemicals and enzymes. We adopted a less sensitive chromogenic approach, while Huber et al used a highly sensitive bioluminescent method. Keeping this in mind, we screened 12 commercially available natural compounds (Table S1), each of which is a major ingredient of traditional herbs with potential antitumor activity. Echinacoside, a compound purified from the parasitic medicinal plant Cistanche salsa (Figure 1C), significantly inhibited the reaction (Figure 1B), with an IC₅₀ of 7.01±2.13 μM (Figure 1D). Adding 50 times more pyrophosphatase had no impact on the result, while adding five times more MTH1 protein significantly decreased the degree of inhibition, suggesting that Echinacoside specifically inhibited the activity of MTH1 in the in vitro enzymatic assay.

Figure 1 In vitro screening of natural compounds.
Notes: (A) A dose–response curve of MTH1 inhibition by a positive control: (S)-crizotinib inhibited MTH1 with an IC₅₀ of 0.5 μM; (B) the inhibition of MTH1 by individual herbal compounds: 15 μM Echinacoside inhibited the activity of MTH1 by >80%; (C) the chemical structure of Echinacoside: a polyphenol glycoside consisting of a phenylpropanoid (red box) and a phenylethanoid (blue box) glycosidically linked to a trisaccharide moiety (a central rhamnose and two side glucose); and (D) a dose–response curve of MTH1 inhibition by a natural compound: Echinacoside inhibited MTH1 with an IC₅₀ of 7.01±2.13 μM.
Abbreviations: IC₅₀, inhibitory concentration; dGTP, deoxyguanosine triphosphate.
Echinacoside inhibited cellular MTH1 to increase intracellular 8-oxoG

Next, we asked if Echinacoside can inhibit intracellular MTH1 activity. Inhibition of cellular MTH1 will result in the increase of intracellular 8-oxoG. Avidin has been shown to bind to 8-oxoG with high specificity; therefore, we used immunofluorescent staining with Cy3-conjugated avidin to compare intracellular 8-oxoG levels in various cancer cell lines before and after Echinacoside treatment. Human MG-63 osteosarcoma, SK-HEP-1 hepatocarcinoma, MCF-7 breast cancer, and SW480 colorectal cancer cells were treated with 0 μM, 15 μM, 30 μM, 60 μM, or 80 μM Echinacoside for 5 hours, 12 hours, or 24 hours. Staining with Cy3-conjugated avidin revealed that treatment with 60 μM Echinacoside for 24 hours clearly and significantly increased the level of cellular 8-oxoG (Cy3-avidin reactive substance) in these cancer cells (Figure 2A and B). Higher concentration (80 μM) of Echinacoside resulted in stronger cellular 8-oxoG staining (Figure 2B), suggesting a dose–response relationship. Similar results were obtained

![Figure 2](image)

**Figure 2** Examination of cellular 8-oxoG, ROS, and DNA damages.

**Notes:** (A) Detection of 8-oxoG by staining with Cy3-conjugated avidin, (B) quantification of data from three independent experiments: treatment of MG-63 cells with 60 μM Echinacoside for 24 h significantly increased the level of cellular 8-oxoG (Cy3-avidin reactive substance) (**P**<0.001 vs vehicle control), (C) measurement of cellular ROS by flow cytometry, (D) quantification of data from three independent experiments: treatment of MG-63 cells with 60 μM Echinacoside for 5 h, 12 h, or 24 h did not change cellular ROS level, (E) immunofluorescent staining of nuclear 53BP1, and (F) quantification of data from three coverslips: significant increase in the number of cells with five or more bright 53BP1 foci was seen as early as 5 h after initiation of treatment with 60 μM Echinacoside (**P**<0.05, **P**<0.001 vs vehicle control).

**Abbreviations:** 8-oxoG, 8-oxoguanine; ROS, reactive oxygen series; DAPI, 4′,6-diamidino-2-phenylindole; DCFH-DA, dichloro-dihydro-fluorescein diacetate; h, hours.
by immunofluorescent staining with a mouse monoclonal anti-8-oxoG antibody (Figure S1A). The concentration of Echinacoside (60 μM) required for a significant increase in cellular 8-oxoG was much higher than the IC₅₀ (7.01 μM) from the in vitro assay. This was likely due to the difference in sensitivity of the two assays. Immunofluorescent staining is far less sensitive than the in vitro enzymatic assay; furthermore, the number of inhibitor molecules that can reach and interact with cellular MTH1 is influenced by complex biological processes; additionally, in the in vitro assay, the less favorite dGTP is used as the substrate, and hence it may be easier (take fewer inhibitors) to inhibit MTH1, resulting in a lower IC₅₀ in the in vitro assay.

Cellular 8-oxoG is generated by ROS, which is antagonized by antioxidants. Thus, increase in cellular ROS or suppression of the activity of antioxidants would also result in increase in cellular 8-oxoG level. Echinacoside itself is a potent antioxidant and thus should enhance rather than suppress the activity of antioxidants. To examine if cellular ROS level was changed by Echinacoside treatment, the same cancer cells were treated with 0 μM, 15 μM, 30 μM, 60 μM, or 80 μM Echinacoside for 5 hours, 12 hours, or 24 hours and then analyzed by flow cytometry after staining with the fluorescent probe 2′,7′-dichlorofluorescin diacetate. The results showed that none of these treatments changed cellular ROS level (Figure 2C and D). Thus, the increased cellular 8-oxoG level was most likely resulted from the inhibition of MTH1 by Echinacoside.

**Echinacoside caused extensive DNA damages specifically in cancer cells**

Incorporation of 8-oxoG into DNA will stimulate BER and MMR, which generate single-strand DNA breaks (SSB) and gaps. Normally, these breaks and gaps are sealed by repair mechanisms involving gap filling and ligation by DNA polymerases and ligases. However, rapid increases in cellular SSB can saturate cellular repair capacity, leading to the formation of numerous double-strand DNA breaks (DSB) and DDR signaling. To examine if the Echinacoside-induced increase in cellular 8-oxoG caused DNA damages, we examined one of the early markers of DNA damage, 53BP1, which binds to sites of DSB as an earliest cellular response to DSB. The MG-63, SK-HEP-1, MCF-7, and SW480 cancer cell lines and the noncancer cell lines human normal liver L-O2, human embryonic kidney HEK 293, and mouse fibroblast NIH/3T3 were treated with 0 μM, 15 μM, 30 μM, 60 μM, or 80 μM Echinacoside for 5 hours, 12 hours, or 24 hours. Fluorescent immunostaining showed that treatment with 60 μM Echinacoside for 24 hours specifically increased the number of cells with five or more strongly stained nuclear 53BP1 foci in all the cancer but not in any of the noncancer cell lines (Figure 2E and F). Significant increase in the number of 53BP1⁺ cells was seen as early as 5 hours after initiation of Echinacoside treatment (Figure 2F). Higher concentration (80 μM) of Echinacoside or longer treatment time (12 hours and 24 hours) resulted in larger increases in both the number of 53BP1⁺ cells (Figure 2F) and the number of cellular 53BP1 foci. Together, these results suggest that the inhibition of MTH1 by Echinacoside caused 8-oxoG accumulation and extensive DNA damages in cancer but not in noncancer cells.

**Echinacoside suppressed cancer cell proliferation**

In cycling cells, unrepaired DNA strand breaks will cause collapse of DNA replication forks, which will then lead to blockage of cell proliferation by induction of cell cycle arrest and apoptosis. To check the effects of Echinacoside on cell growth and proliferation, we first analyzed the growth of Echinacoside-treated MG-63, SK-HEP-1, MCF-7, and SW480 cancer cells by a colony formation assay. The results showed that the cancer cells treated with 60 μM or 80 μM Echinacoside formed much fewer colonies, and the colonies that formed were much smaller (Figure 3A and B), indicating greatly suppressed growth potential. Next, we analyzed the proliferation of these cancer cells, together with the L-O2, HEK 293, and NIH/3T3 noncancer cells by an MTT assay. The results showed that Echinacoside dose dependently inhibited the proliferation of the cancer but not the noncancer cells (Figure 3C). Time-course study of cancer cells treated with 60 μM Echinacoside showed that after 5 hours, there was no significant difference between nontreatment and treatment groups, but after 12 hours, cancer cell proliferation was significantly inhibited by 60 μM Echinacoside (Figure 3D).

**Echinacoside induced cell cycle arrest**

In accordance with the observations on cell growth and proliferation, Western blot analysis showed that 24 hours treatment with 60 μM and 80 μM Echinacoside significantly increased the protein level of the G1/S-CDK blocker and DNA synthesis inhibitor p21Cip/WAF1 in the MG-63, SK-HEP-1, MCF-7, and SW480 cancer cells (Figure 4A and B). Moreover, similar to 53BP1, significant increase in p21 protein level was seen as early as 5 hours after initiation of Echinacoside treatment (Figure 4B). Analysis of the number of cells at different
stages of cell cycle by flow cytometry revealed that Echinacoside treatment dose dependently reduced the percentage of cells in both S and G2/M phases, while the percentage of cells in G1 phase increased (Figure 4C and D). After 80 μM Echinacoside treatment of MG-63 cells for 24 hours, cells in G2/M phase decreased from 15% to nearly zero, and cells in S phase decreased from 37% to 17%, while cells in G0/G1 phase increased from 43% to 80% (Figure 4E). These results indicate that treatment with Echinacoside induced cell cycle arrest and blocked the cancer cells in G1 phase.

Echinacoside induced apoptosis in cancer cells

Consistent with observations on cell proliferation, Western blot analysis showed that treatment with 60 μM and 80 μM Echinacoside for 24 hours increased the levels of active caspase-3 and cleaved poly (ADP-ribose) polymerase proteins in the cancer cells (Figure 5A and B), suggesting induction of caspase-dependent apoptosis. We then examined several cellular markers of apoptosis. First, the nuclear morphology of Echinacoside-treated cancer cells was revealed by staining with the DNA dye DAPI, which showed that 24 hours treatment with 60 μM and 80 μM Echinacoside increased the number of hallmarks of apoptosis, including pyknosis and condensed chromatin (brighter nuclei) (Figure 5C). Second, the DNA extracted from similarly treated cancer cells was analyzed by electrophoresis on agarose gel, which revealed a typical apoptotic ladder pattern (Figure S1B). Finally, cellular active caspase-3 was detected by immunofluorescent staining, which revealed strong activated caspase-3 signals in Echinacoside-treated cancer cells (Figure S1C).

Next, the percentage of apoptotic cells was measured by Annexin V-FITC and PI double staining and flow cytometry. Analysis of cells treated with 0 μM, 15 μM, 30 μM, 60 μM, 80 μM, or 160 μM Echinacoside for 2 hours, 5 hours, 12 hours, or 24 hours showed that 60 μM or higher concentrations of Echinacoside induced significant apoptosis in the MG-63, SK-HEP-1, MCF-7, and SW480 cancer cells (Figure 6A), but not in the noncancer L-O2, HEK 293, and NIH/3T3 cells (Figure S2). After treatment of MG-63 cells with 60 μM, 80 μM, or 160 μM Echinacoside for 24 hours, the percentage of apoptotic cells increased from 8.89% to 33.72%, 39.01%, and 48.12%, respectively (Figure 6A). Time-course study showed that after 5 hours, there was no significant difference between nontreatment and treatment groups, but significant apoptosis was seen after treatment with 60 μM or higher concentrations of Echinacoside for 12 hours (Figures 6B and S3).
**Figure 4** Analysis of cell cycle.

**Notes:** (A and B) Western blot analysis of p21 and quantification of data from three independent experiments: significantly upregulated p21 was seen in MG-63 cells treated with 60 μM Echinacoside for 5 h and longer (**P<0.001 vs vehicle control**). (C–E) Cell cycle analysis: MG-63 cells were treated with 0 μM (C) and 60 μM (D) Echinacoside and quantitative data from three independent experiments are shown (E); Echinacoside significantly reduced the percentage of cells in both S and G2/M phases, while the percentage of cells in G1 phase increased (**P<0.01, ***P<0.001 vs vehicle control).**

**Abbreviations:** h, hours; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Finally, measurement of mitochondrial membrane potential by the JC-1 fluorescent dye clearly showed a prominent loss of mitochondrial membrane potential after treatment with 60 μM Echinacoside for 12 hours (Figure 6C), but not after 5 hours, indicating the activation of the intrinsic apoptosis pathway following the DNA damages caused by elevated 8-oxodG.

Discussion

Echinacoside is a natural compound isolated from the medicinal plants Cistanche and Echinacea. It has been shown to possess versatile health promotional and disease preventive properties, including neural protection, hepatoprotection, and anti-inflammation, antifatigue, antisenescence, antidiabetes, and antitumor activities. The best known and accepted bioactivity of Echinacoside is its antioxidative and ROS-scavenging action; however, it has also been shown to cause oxidative DNA damages in cancer cells, with the underlying mechanisms remaining unclear. In the present study, using a high-throughput in vitro screening assay, we found that Echinacoside effectively inhibited the MTH1-catalyzed enzymatic reaction. Increasing the amount of the MTH1 enzyme decreased the degree of inhibition, while increasing the amount of the inorganic pyrophosphatase did not affect the inhibition, indicating that Echinacoside specifically inhibited the activity of MTH1 in the in vitro assay. Treatment of different human cancer cell lines with Echinacoside caused significant elevation of cellular 8-oxoG level without changing the cellular ROS level. Given that Echinacoside itself is a potent antioxidant, these results suggested that the increased intracellular 8-oxoG level was likely resulted from the inhibition of cellular MTH1 by Echinacoside.

Treatment with Echinacoside caused extensive DNA damages and significant upregulation of the G/S-CDK blocker p21, which were followed by marked apoptotic cell death and suppression of cell proliferation specifically in cancer but not in the noncancer cells. Furthermore, a prominent loss of mitochondrial membrane potential after
Echinacoside treatment indicated activation of the intrinsic apoptosis pathway. Echinacoside-induced DNA damages and upregulation of p21 were observed within 5 hours of treatment, while cancer cell apoptosis, disruption of mitochondrial membrane potential, and growth inhibition were observed 12 hours after initiation of treatment. These data support that cancer cell apoptosis and growth inhibition were the results of the extensive DNA damages caused by the inhibition of MTH1. Recent studies have shown that reduction in the size of cellular dNTP pool could also induce DNA replication stress and DNA damages. However, >200% increase in 8-oxoG level in the Echinacoside-treated cancer cells argues against the possibility of a reduced dNTP pool size, and Bcl2, a protein that reduces dNTP pool size, was significantly decreased in Echinacoside-treated SW480 cancer cells; moreover, our data clearly showed that Echinacoside directly inhibited MTH1, which could at least be partially responsible for the DNA damages and cellular effects caused by Echinacoside.

The dNTP pool is a critical target of ROS, and oxidized dNTPs are important sources of oxidative DNA damages. Repair-associated DNA SSBs and DSBs can lead to cellular senescence and apoptosis, which are implicated in aging and aging-related diseases, and also serve as a barrier for tumorigenesis. Thus, reducing ROS-induced DNA damages by antioxidants is believed to be beneficial to the overall health. However, several recent studies have shown that antioxidants could also promote development of some types of cancer.

Cancer cells generate much higher ROS and are critically dependent on efficient elimination of oxidized nucleotides for survival and proliferation. Overexpression of MTH1 is the most important strategy cancer cells use to cope with the lethal burden of oxidized dNTPs. Inhibition of MTH1 efficiently killed cancer cells, while targeting MTH1 in normal cells had no impact on survival, and MTH1 knockout mice were largely normal. Consistently, we also showed that treatment with Echinacoside induced apoptosis and suppressed cell proliferation specifically in cancer but not in noncancer cells. Thus, unlike current chemotherapies and radiotherapies that target normal and tumor cells indiscriminately, the inhibition of MTH1 kills cancer cells highly selectively by using the abundant oxidized nucleotide precursors in tumors. On the other hand, therapies targeting genotype differences between normal and specific types of cancer in a personalized approach have shown impressive results, but they are also limited by the

Figure 6 Induction of apoptosis by Echinacoside.

Notes: (A) Analysis of Annexin V-FITC- and propidium iodide-stained cells by flow cytometry, (B) time-course analysis of apoptosis induction: significant apoptosis was seen in MG-63 cells treated with 60 μM or higher concentrations of Echinacoside for 12 h (**P<0.001 vs control), and (C) measurement of mitochondrial membrane potential: MG-63 cells were treated with 60 μM Echinacoside for 5 h, 12 h, and 24 h; increase in the intensity of green at the 12 h point showed significant disruption of mitochondrial membrane potential.

Abbreviations: h, hours; PI, propidium iodide; FITC, fluorescein isothiocyanate.
high degree of intratumor heterogeneity and high mutation rates in cancer cells. In contrast, inhibition of MTH1 targets a phenotype that distinguishes most cancer cells from normal cells, and hence represents a novel anticancer strategy that is not limited by genetic adaptations. Interestingly, small molecule antagonists of the antiapoptosis protein Bcl2 have been developed and were demonstrated to be promising novel anticancer agents. Given their complementary mechanisms of action, combining MTH1 inhibitors and apoptosis-promoting chemicals would create an exciting new generation of anticancer drugs.

For the first time, we demonstrated a new function for Echinacoside as an anticancer natural compound. In the in vitro assay, Echinacoside inhibited MTH1 with an IC50 of 7.01 μM. This IC50 value is higher than that of the MTH1 inhibitors reported so far. Using (S)-crizotinib as a positive control, we showed that our assay is sevenfold less sensitive than that used by Huber et al. Thus, the actual IC50 of Echinacoside is likely to be lower. Nevertheless, to develop it as a therapeutic agent, the efficacy of the natural Echinacoside molecule will probably need to be improved. As a natural product that has been used as a herbal medicine for long time, Echinacoside could serve as a good chemical scaffold for developing efficient and probably safe MTH1 inhibitors. Given that natural products have been a rich source of novel chemical scaffolds for rational structure-based drug design, approaches similar to what we used here, together with the vast interests in natural products for drug discovery, will be useful in finding target-based, effective, and safe new drugs.

Acknowledgment
This study was supported by a startup fund from Jilin University.

Disclosure
The authors report no conflicts of interest in this work.

References
Supplementary materials

Table S1 List of herbal compounds used in the in vitro screening

<table>
<thead>
<tr>
<th>Name</th>
<th>CAS registry number</th>
<th>Catalog #</th>
<th>Purity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echinacoside</td>
<td>82854-37-3</td>
<td>YY90282</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Quercetin</td>
<td>117-39-5</td>
<td>YY90083</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Scutellarin</td>
<td>27740-01-8</td>
<td>YY90017</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Magnolol</td>
<td>528-43-8</td>
<td>YY90180</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Jatrorrhizine</td>
<td>960383-96-4</td>
<td>YY90285</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Salidroside</td>
<td>10338-51-9</td>
<td>YY90076</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Hyperoside</td>
<td>482-36-0</td>
<td>YY90090</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Salidroside</td>
<td>76281-02-4</td>
<td>YY90380</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Glycyrrheticin</td>
<td>1449-05-4</td>
<td>YY90038</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Kaempferol</td>
<td>520-18-3</td>
<td>YY90129</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Rutin</td>
<td>153-18-4</td>
<td>YY90103</td>
<td>HPLC &gt;98%</td>
</tr>
<tr>
<td>Piperine</td>
<td>94-62-2</td>
<td>YY90200</td>
<td>HPLC &gt;98%</td>
</tr>
</tbody>
</table>

Abbreviations: HPLC, high-performance liquid chromatography; CAS, Chemical Abstracts Service.

![Figure S1](Continued)
Figure S1 Examination of cellular 8-oxoG and apoptosis.
Notes: (A) Detection of 8-oxoG by a monoclonal anti-8-oxoG antibody; 8-oxoG signal was revealed by an Alexa 488-conjugated secondary antibody; and treatment of MG-63 cells with 60 μM and 80 μM Echinacoside for 24 h increased the level of 8-oxoG. (B) Analysis of cancer cell DNA by electrophoresis on 2% agarose gel: treatment of MG-63 cells with 80 μM Echinacoside for 24 h produced a typical apoptosis ladder pattern; and (C) Immunofluorescent staining of active caspase-3: strongly activated caspase-3 signals were detected in MG-63 cells treated with 60 μM Echinacoside for 24 h.
Abbreviations: 8-oxoG, 8-oxoguanine; h, hours; DAPI, 4′,6-diamidino-2-phenylindole.

Figure S2 Flow cytometry analysis of apoptosis in noncancer cells.
Notes: (A) Normal human liver L-O2 cells, (B) human embryonic kidney HEK 293 cells, and (C) mouse NIH/3T3 fibroblast cells. Treatment with 60 μM and 80 μM Echinacoside for 24 h did not change the percentage of apoptotic cells in these noncancer cell lines.
Abbreviations: h, hours; PI, propidium iodide; FITC, fluorescein isothiocyanate.
Figure S3 Time-course analysis of apoptosis.

Notes: MG-63 cells were treated with 60 μM Echinacoside for 2 h, 5 h, and 12 h, and significant apoptosis was seen after treatment for 12 h.

Abbreviations: h, hours; PI, propidium iodide.